Al-Dawaa Medical Services Future Growth
Future criteria checks 3/6
Al-Dawaa Medical Services is forecast to grow earnings and revenue by 14.1% and 6.8% per annum respectively. EPS is expected to grow by 12.1% per annum. Return on equity is forecast to be 30.3% in 3 years.
Key information
14.1%
Earnings growth rate
12.1%
EPS growth rate
Consumer Retailing earnings growth | 19.7% |
Revenue growth rate | 6.8% |
Future return on equity | 30.3% |
Analyst coverage | Good |
Last updated | 09 Dec 2024 |
Recent future growth updates
Recent updates
Al-Dawaa Medical Services Company (TADAWUL:4163) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 14Benign Growth For Al-Dawaa Medical Services Company (TADAWUL:4163) Underpins Its Share Price
Sep 24The Returns At Al-Dawaa Medical Services (TADAWUL:4163) Aren't Growing
Jul 29Market Still Lacking Some Conviction On Al-Dawaa Medical Services Company (TADAWUL:4163)
Jun 03Al-Dawaa Medical Services' (TADAWUL:4163) Strong Earnings Are Of Good Quality
May 08Al-Dawaa Medical Services (TADAWUL:4163) Hasn't Managed To Accelerate Its Returns
Apr 05Al-Dawaa Medical Services (TADAWUL:4163) Has Some Way To Go To Become A Multi-Bagger
Dec 26Al-Dawaa Medical Services (TADAWUL:4163) Has Announced A Dividend Of SAR1.25
Sep 03Return Trends At Al-Dawaa Medical Services (TADAWUL:4163) Aren't Appealing
Jul 13Is Al-Dawaa Medical Services Company (TADAWUL:4163) Expensive For A Reason? A Look At Its Intrinsic Value
Jun 22Returns On Capital Signal Tricky Times Ahead For Al-Dawaa Medical Services (TADAWUL:4163)
Apr 10Some Shareholders Feeling Restless Over Al-Dawaa Medical Services Company's (TADAWUL:4163) P/E Ratio
Mar 14Is Al-Dawaa Medical Services Company (TADAWUL:4163) Trading At A 34% Discount?
Dec 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 7,199 | 500 | 508 | 822 | 5 |
12/31/2025 | 6,722 | 439 | 429 | 749 | 6 |
12/31/2024 | 6,298 | 368 | 610 | 909 | 4 |
9/30/2024 | 6,187 | 359 | 405 | 666 | N/A |
6/30/2024 | 6,000 | 355 | 474 | 703 | N/A |
3/31/2024 | 5,850 | 348 | 597 | 836 | N/A |
12/31/2023 | 5,741 | 329 | 502 | 726 | N/A |
9/30/2023 | 5,742 | 326 | 704 | 848 | N/A |
6/30/2023 | 5,612 | 303 | 716 | 881 | N/A |
3/31/2023 | 5,485 | 295 | 529 | 743 | N/A |
12/31/2022 | 5,372 | 305 | 528 | 778 | N/A |
9/30/2022 | 5,212 | 285 | 266 | 651 | N/A |
6/30/2022 | 5,163 | 275 | 142 | 519 | N/A |
3/31/2022 | 5,119 | 247 | 217 | 561 | N/A |
12/31/2021 | 5,034 | 239 | 361 | 670 | N/A |
9/30/2021 | 4,977 | 254 | 413 | 649 | N/A |
6/30/2021 | 4,958 | 300 | 400 | 644 | N/A |
3/31/2021 | 4,932 | 286 | 348 | 566 | N/A |
12/31/2020 | 4,962 | 246 | 166 | 378 | N/A |
12/31/2019 | 3,962 | 233 | 356 | 515 | N/A |
12/31/2018 | 3,797 | 228 | 244 | 392 | N/A |
12/31/2017 | 3,376 | 121 | N/A | 568 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4163's forecast earnings growth (14.1% per year) is below the savings rate (14.7%).
Earnings vs Market: 4163's earnings (14.1% per year) are forecast to grow faster than the SA market (6% per year).
High Growth Earnings: 4163's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4163's revenue (6.8% per year) is forecast to grow faster than the SA market (-0.5% per year).
High Growth Revenue: 4163's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4163's Return on Equity is forecast to be high in 3 years time (30.3%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/19 16:56 |
End of Day Share Price | 2024/12/19 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Al-Dawaa Medical Services Company is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Duaa AlFadda | BofA Global Research |
Alia El Mehelmy | CI Capital Research |
Michel Salameh | Citigroup Inc |